ResearcherSecond Military Medical UniversityActive in the last 2 years
Huojun Zhang
Matched on ORCID iD 0009-0003-4327-3498; OpenAlex author ID A5101665820. Sources: OpenAlex.
Their work
- Papers
- 32 (first author 0, last author 28)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 30
2016: 1 paper · 2017: 2 papers · 2018: 6 papers · 2019: 2 papers · 2020: 4 papers · 2021: 6 papers · 2022: 4 papers · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 3 papers
Papers 32
- Multifunctional Nanovaccine-Radiotherapy Synergy Drives Anti-Tumor Immunity via Multi-Cascade Cell Death for Pancreatic Cancer Therapy. Last author DOI 10.1002/advs.77651↗
- AURKA promotes radioresistance in pancreatic cancer via GSK3β-mediated PTEN phosphorylation at T366. Last author DOI 10.1016/j.yexcr.2026.114986↗
- Rescue Radiosensitization of Pancreatic Cancer via PD-L1/TGF-β1 Dual-Blockade Nanotherapy as Evaluated in 3-Dimensional Microtumors. Co-author DOI 10.34133/bmr.0335↗
- Stereotactic body radiation therapy plus adoptive vNKT cell therapy for pancreatic cancer: protocol of a phase II trial. Last author DOI 10.1080/1750743x.2025.2533112↗
- Immune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: Biomarker analysis of a randomized phase 2 trial. Last author DOI 10.1016/j.radonc.2023.109941↗
- Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patients with metastatic pancreatic cancer. Last author DOI 10.1186/s13014-024-02493-8↗
- Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body radiotherapy dose escalation plus gemcitabi… Last author DOI 10.1016/j.eclinm.2022.101764↗
- Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer… Last author DOI 10.1016/s1470-2045(22)00066-3↗
- Biologically effective doses of 60-70Gy versus >70Gy of stereotactic body radiotherapy (SBRT) combined with chemotherapy in locally advanced pancreatic cancer:… Last author DOI 10.1136/bmjopen-2021-049382↗
- Uniform expansion vs. non-uniform expansion of gross tumor volume based on recurrence patterns to form planning target volume of stereotactic body radiation th… Last author DOI 10.21203/rs.3.rs-1919548/v1↗
- Dose evaluations of organs at risk and predictions of gastrointestinal toxicity after re-irradiation with stereotactic body radiation therapy for pancreatic ca… Last author DOI 10.3389/fonc.2022.1021058↗
- Stereotactic body radiation therapy with sequential S-1 for patients with locally advanced pancreatic cancer and poor performance status: An open-label, single… Last author DOI 10.1016/j.radonc.2021.07.009↗
- Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer… Last author DOI 10.1016/s1470-2045(21)00286-2↗
- Stereotactic body radiotherapy plus pembrolizumab and trametinib for pancreatic cancer - Authors' reply. Last author DOI 10.1016/s1470-2045(21)00529-5↗
- Personalized designs of adjuvant radiotherapy for pancreatic cancer based on molecular profiles. Last author DOI 10.1111/cas.14486↗
- Development and Validation of Multicenter Predictive Nomograms for Locally Advanced Pancreatic Cancer After Chemoradiotherapy. Last author DOI 10.3389/fonc.2021.688576↗
- Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotactic Body Radiotherapy: Analysis of 24 Cons… Last author DOI 10.3389/fonc.2021.729490↗
- Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for promoting therapeutic efficiency. Co-author DOI 10.1016/j.jconrel.2020.06.001↗
- Failure patterns and outcomes of dose escalation of stereotactic body radiotherapy for locally advanced pancreatic cancer: a multicenter cohort study. Last author DOI 10.1177/1758835920977155↗
- Prognostic value of 18F-FDG PET /CT metabolic parameters in patients with locally advanced pancreatic Cancer treated with stereotactic body radiation therapy. Last author DOI 10.1186/s40644-020-00301-6↗
- Validation of the eighth edition of the AJCC staging system for patients with pancreatic adenocarcinoma initially receiving chemoradiotherapy and proposal of m… Last author DOI 10.20892/j.issn.2095-3941.2019.0101↗
- Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Tar… Last author DOI 10.1016/j.ijrobp.2019.01.075↗
- Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: stu… Co-author DOI 10.1186/s13014-019-1254-8↗
- Prospective analysis of different combined regimens of stereotactic body radiation therapy and chemotherapy for locally advanced pancreatic cancer. Last author DOI 10.1002/cam4.1553↗
- Prediction of overall survival after re-irradiation with stereotactic body radiation therapy for pancreatic cancer with a novel prognostic model (the SCAD scor… Last author DOI 10.1016/j.radonc.2018.08.012↗
- Optimization of dose distributions of target volumes and organs at risk during stereotactic body radiation therapy for pancreatic cancer with dose-limiting aut… Last author DOI 10.1186/s13014-018-0956-7↗
- Pre-treatment DWI as a predictor of overall survival in locally advanced pancreatic cancer treated with Cyberknife radiotherapy and sequential S-1 therapy. Co-author DOI 10.1186/s40644-018-0139-7↗
- Stereotactic body radiation therapy plus induction or adjuvant chemotherapy for early stage but medically inoperable pancreatic cancer: A propensity score-matc… Last author DOI 10.2147/cmar.s163655↗
- Health-related quality of life for gemcitabine and nab-paclitaxel plus radiotherapy versus gemcitabine and S-1 plus radiotherapy in patients with metastatic pa… Last author DOI 10.2147/cmar.s166713↗
- Prognostic role of stereotactic body radiation therapy for elderly patients with advanced and medically inoperable pancreatic cancer. Last author DOI 10.1002/cam4.1164↗
- Dose escalation of Stereotactic Body Radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer patients with CyberKnife: protocol of a phase I st… Last author DOI 10.1186/s13014-016-0760-1↗
- Safety and efficacy of stereotactic body radiation therapy combined with S-1 simultaneously followed by sequential S-1 as an initial treatment for locally adva… Last author DOI 10.1136/bmjopen-2016-013220↗
Closest collaborators
The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Xiaofei Zhu · 28 shared papers, 2016–2026 · strength 3.70
- Paper Multifunctional Nanovaccine-Radiotherapy Synergy Drives Anti-Tumor Immunity via Multi-Cascade Cell Death for Pancreatic… DOI 10.1002/advs.77651↗
- Paper Immune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: Biomarker analysis of a… DOI 10.1016/j.radonc.2023.109941↗
- Paper Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patient… DOI 10.1186/s13014-024-02493-8↗
- Yangsen Cao · 25 shared papers, 2016–2025 · strength 3.36
- Paper Stereotactic body radiation therapy plus adoptive vNKT cell therapy for pancreatic cancer: protocol of a phase II trial. DOI 10.1080/1750743x.2025.2533112↗
- Paper Immune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: Biomarker analysis of a… DOI 10.1016/j.radonc.2023.109941↗
- Paper Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patient… DOI 10.1186/s13014-024-02493-8↗
- Lingong Jiang · 14 shared papers, 2020–2025 · strength 2.29
- Paper Stereotactic body radiation therapy plus adoptive vNKT cell therapy for pancreatic cancer: protocol of a phase II trial. DOI 10.1080/1750743x.2025.2533112↗
- Paper Immune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: Biomarker analysis of a… DOI 10.1016/j.radonc.2023.109941↗
- Paper Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patient… DOI 10.1186/s13014-024-02493-8↗
- Yusheng Ye · 11 shared papers, 2020–2024 · strength 1.78
- Paper Immune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: Biomarker analysis of a… DOI 10.1016/j.radonc.2023.109941↗
- Paper Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patient… DOI 10.1186/s13014-024-02493-8↗
- Paper Effect of stereotactic body radiotherapy dose escalation plus pembrolizumab and trametinib versus stereotactic body rad… DOI 10.1016/j.eclinm.2022.101764↗
- Wenyu Liu · 8 shared papers, 2018–2025 · strength 1.38
- Paper Stereotactic body radiation therapy plus adoptive vNKT cell therapy for pancreatic cancer: protocol of a phase II trial. DOI 10.1080/1750743x.2025.2533112↗
- Paper Immune profiling of pancreatic cancer for radiotherapy with immunotherapy and targeted therapy: Biomarker analysis of a… DOI 10.1016/j.radonc.2023.109941↗
- Paper Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patient… DOI 10.1186/s13014-024-02493-8↗
- Shuiwang Qing · 13 shared papers, 2016–2021 · strength 1.21
- Paper Personalized designs of adjuvant radiotherapy for pancreatic cancer based on molecular profiles. DOI 10.1111/cas.14486↗
- Paper Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotacti… DOI 10.3389/fonc.2021.729490↗
- Paper Development and Validation of Multicenter Predictive Nomograms for Locally Advanced Pancreatic Cancer After Chemoradiot… DOI 10.3389/fonc.2021.688576↗
- Yuxin Shen · 10 shared papers, 2016–2021 · strength 0.88
- Paper Personalized designs of adjuvant radiotherapy for pancreatic cancer based on molecular profiles. DOI 10.1111/cas.14486↗
- Paper Re-Irradiation With Stereotactic Body Radiotherapy for In-Field Recurrence of Pancreatic Cancer After Prior Stereotacti… DOI 10.3389/fonc.2021.729490↗
- Paper Validation of the eighth edition of the AJCC staging system for patients with pancreatic adenocarcinoma initially recei… DOI 10.20892/j.issn.2095-3941.2019.0101↗
- Di Chen · 2 shared papers, 2020–2026 · strength 0.41
- Paper Rescue Radiosensitization of Pancreatic Cancer via PD-L1/TGF-β1 Dual-Blockade Nanotherapy as Evaluated in 3-Dimensional… DOI 10.34133/bmr.0335↗
- Paper Validation of the eighth edition of the AJCC staging system for patients with pancreatic adenocarcinoma initially recei… DOI 10.20892/j.issn.2095-3941.2019.0101↗
- Di Chen · 2 shared papers, 2020–2026 · strength 0.39
- Paper AURKA promotes radioresistance in pancreatic cancer via GSK3β-mediated PTEN phosphorylation at T366. DOI 10.1016/j.yexcr.2026.114986↗
- Paper Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for… DOI 10.1016/j.jconrel.2020.06.001↗
- Gang Jin · 3 shared papers, 2019–2022 · strength 0.38
- Paper Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine… DOI 10.1016/s1470-2045(22)00066-3↗
- Paper Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine… DOI 10.1016/s1470-2045(21)00286-2↗
- Paper Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for bord… DOI 10.1186/s13014-019-1254-8↗
- Wei Li · 1 shared paper, 2026 · strength 0.30
- Wei Jing · 1 shared paper, 2026 · strength 0.30
- Chengyi Huang · 1 shared paper, 2026 · strength 0.27
- Xiaofei Zhu · 1 shared paper, 2025 · strength 0.25
- Ting‐Shi Su · 2 shared papers, 2020–2021 · strength 0.23
- Paper Development and Validation of Multicenter Predictive Nomograms for Locally Advanced Pancreatic Cancer After Chemoradiot… DOI 10.3389/fonc.2021.688576↗
- Paper Failure patterns and outcomes of dose escalation of stereotactic body radiotherapy for locally advanced pancreatic canc… DOI 10.1177/1758835920977155↗
- Shengnan Ren · 1 shared paper, 2020 · strength 0.13
- Changjing Zuo · 1 shared paper, 2020 · strength 0.13
- Anyu Zhang · 1 shared paper, 2020 · strength 0.13
- Xixu Zhu · 1 shared paper, 2021 · strength 0.12
- Jianping Lu · 1 shared paper, 2018 · strength 0.10
- Yu Zhang · 1 shared paper, 2018 · strength 0.10
- Suizhi Gao · 1 shared paper, 2019 · strength 0.09
- Yun Bian · 1 shared paper, 2019 · strength 0.09
- Kai Cao · 1 shared paper, 2019 · strength 0.09
- Shiwei Guo · 1 shared paper, 2019 · strength 0.09
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.